Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ. Genovese MC, et al. Among authors: woodworth t. Arthritis Rheum. 2008 Oct;58(10):2968-80. doi: 10.1002/art.23940. Arthritis Rheum. 2008. PMID: 18821691 Free article. Clinical Trial.
Assessing single joints in arthritis clinical trials.
Giles JT, Mease P, Boers M, Bresnihan B, Conaghan PG, Heald A, Maksymowych WP, Maillefert JF, Simon L, Tsuji W, Wakefield R, Woodworth T, Schumacher HR, Bingham CO 3rd. Giles JT, et al. Among authors: woodworth t. J Rheumatol. 2007 Mar;34(3):641-7. J Rheumatol. 2007. PMID: 17343312
A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.
Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, van den Bosch F, Bresnihan B, Breedveld FC, Dinant HJ, Legay F, Gram H, Loetscher P, Schmouder R, Woodworth T, Tak PP. Haringman JJ, et al. Among authors: woodworth t. Arthritis Rheum. 2006 Aug;54(8):2387-92. doi: 10.1002/art.21975. Arthritis Rheum. 2006. PMID: 16869001 Free article. Clinical Trial.
Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
Garnero P, Thompson E, Woodworth T, Smolen JS. Garnero P, et al. Among authors: woodworth t. Arthritis Rheum. 2010 Jan;62(1):33-43. doi: 10.1002/art.25053. Arthritis Rheum. 2010. PMID: 20039425 Free article. Clinical Trial.
Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group.
Klokker L, Tugwell P, Furst DE, Devoe D, Williamson P, Terwee CB, Suarez-Almazor ME, Strand V, Woodworth T, Leong AL, Goel N, Boers M, Brooks PM, Simon LS, Christensen R. Klokker L, et al. Among authors: woodworth t. J Rheumatol. 2017 Dec;44(12):1916-1919. doi: 10.3899/jrheum.161105. Epub 2016 Oct 15. J Rheumatol. 2017. PMID: 27744393
Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials.
Klokker L, Berthelsen DB, Woodworth T, Andersen KM, Furst DE, Devoe D, Williamson PR, Suarez-Almazor ME, Strand V, Leong AL, Goel N, Boers M, Brooks PM, March L, Sloan VS, Tugwell P, Simon LS, Christensen R. Klokker L, et al. Among authors: woodworth t. J Rheumatol. 2019 Sep;46(9):1173-1178. doi: 10.3899/jrheum.190196. Epub 2019 May 1. J Rheumatol. 2019. PMID: 31043547
118 results